Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

• Status: Completed
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of lymphocytic colitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr. Falk Pharma GmbH
• Treatments: Budesonide; Mesalamine

Criteria

Inclusion Criteria:

• Signed informed consent

• Symptoms and signs of indication of lymphocytic colitis

Exclusion Criteria:

• Infectious diarrhoea,

• Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract or endoscopic-histological findings Celiac disease

• Pregnancy or breast-feeding,

• Participation in an other clinical trial